Background
==========

Cushing's syndrome (CS) is an uncommon disorder, with an incidence of 0.7--2.4 cases per million per year ([@bib1]). The majority of cases result from adrenocorticotropin (ACTH) hypersecretion, usually from a pituitary adenoma. In a smaller percentage of cases, ACTH is over-secreted from a non-pituitary source, such as bronchial carcinoid, small-cell lung carcinoma or thyroid medullary carcinoma ([@bib1]). CS resulting from an ACTH-secreting pheochromocytoma is an even more rare and challenging condition that combines hypercortisolism and catecholamine excess, leading to severe and potentially life-threatening complications ([@bib2]). About 60 cases have been reported in literature so far ([@bib2]). The gold standard treatment of this condition is adrenalectomy, preceded by adequate medical preparation to obtain adequate control of hormonal hypersecretions. Here, we report a case of CS due to an ACTH-secreting pheochromocytoma and the beneficial effect of the combined ketoconazole-somatostatin analog treatment in the pre-surgical management of the patient.

Case presentation
=================

A 45-year-old woman on oral hypoglycemic therapy (metformin 850 mg b.i.d. and pioglitazone 15 mg b.i.d.) due to a recent diagnosis of type 2 diabetes mellitus contacted the emergency department of our hospital complaining of a rapid and consistent worsening of glycemic control, together with asthenia, fever and weight loss. A few days before, she had been evaluated in the outpatient clinic of the Department of Cardiology for palpitations and was found to be hypertensive. There was no history of smoking, alcohol, drugs abuse and allergies. Family history for endocrine diseases was negative except for type 2 diabetes. Her weight was 60 kg and the height 167 cm (BMI, 21.5 kg/m^2^). Clinical examination confirmed hypertension (180/90 mmHg) with a pulse rate of 110 bpm and revealed an evident sarcopenia and dehydration. Laboratory tests showed leucocytosis (18.000) with raised polymorphs (93.5%), hypokalemia (2.73 mmol/L), hyperglycemia (serum glucose 242 mg/dL), and normal renal and liver functions. The patient received oral and i.v. potassium, amlodipine 5 mg orally and s.c. insulin therapy. She was subsequently admitted to our unit.

Investigation
=============

Results of the hormonal assessment are depicted in [Table 1](#tbl1){ref-type="table"}. Urinary and serum cortisol and plasma ACTH were markedly increased and dexamethasone 1 mg overnight failed to suppress serum cortisol levels, consistently with a condition of ACTH-dependent Cushing's syndrome. Aldosterone/renin ratio was within the normal limits. Ancillary findings were secondary hypothyroidism, central hypogonadism, and low IGF-1 levels, as usually observed in cases of overt hypercortisolism. Table 1Pre-operative hormonal assessment of the patient.Biochemical parametersValuesNormal range Cortisol (nmol/L)2237138--717 UFC (nmol/day)\>34 4831931--8827 ACTH (pmol/L)87.52--11.5 TSH (μU/mL)0.170.25--5 Free T4 (pmol/L)6.912--22 Free T3 (pmol/L)1.03--6 Estradiol (pmol/L)\<92-- LH (mU/mL)1.2-- IGF-1 (nmol/L)8.512--32 Cortisol after DST 1 mg (nmol/L)2300\<50 Cortisol after DST 8 mg (nmol/L)2364-- 24-h urine adrenaline (nmol/day)9829--122 24-h urine noradrenaline (nmol/day)88471--506 24-h urine metanephrine (nmol/day)2807\<1622 24-h urine normetanephrine (nmol/day)1135\<2130 Chromogranin A (nmol/L)4.160.5--3 NSE (μg/L)17.90--12.5CRH stimulation test ACTH (pmol/L)  Baseline66--  Peak74-- Cortisol (nmol/L)  Baseline2265--  Peak2480--[^1]

Serum CRH stimulation test failed to significantly increase both serum cortisol and plasma ACTH levels ([Table 1](#tbl1){ref-type="table"}). Serum cortisol levels remained unchanged after high-dose (8 mg) dexamethasone overnight administration. Taken together, all these findings were consistent with a non-pituitary (ectopic) source of the ACTH secretion. Following a s.c. 100 μg octreotide administration, a 50% decrease in ACTH levels and 25% decrease in cortisol levels were observed ([Table 2](#tbl2){ref-type="table"}). The octreotide challenge test was performed under the surveillance of an expert physician, with a close monitoring of vital parameters. Table 2Results of the somatostatin challenge test.Time (min)ACTH (pmol/L)Cortisol (nmol/L)092228960521820120511931180611725240392179300541986[^2]

A computed tomography (CT) of the thorax and abdomen identified a 3 cm left adrenal mass, showing features consistent with a non-adenoma ([Fig. 1](#fig1){ref-type="fig"}). Magnetic resonance imaging (MRI) of the pituitary gland was normal. Further hormonal investigation showed high concentrations of urinary catecholamines and metanephrines, suggesting the presence of a pheochromocytoma. Chromogranin A (CGA) and neuron-specific enolase (NSE) were both elevated ([Table 1](#tbl1){ref-type="table"}). Figure 1Coronal view at CT scan of the abdomen, showing a 30 mm high-density left adrenal mass.

Treatment
=========

According to the whole picture, pre-operative management of the patient included alpha and beta blocker administration (doxazosin 8 mg b.i.d. for 14 days, followed by doxazosin 8 mg b.i.d. plus atenolol 50 mg b.i.d.), ketoconazole (200 mg b.i.d.) and octreotide (100 μg subcutaneously t.i.d.).

Preoperative biochemical controls showed a significant reduction of plasma ACTH (204 pg/mL) and serum cortisol (46.6 μg/dL) levels. An optimal control of blood pressure and pulse rate was achieved. Subsequently, the patient underwent a laparoscopic left adrenalectomy without any complication. Histopathological and immunohistochemical assessment confirmed an ACTH-producing pheochromocytoma expressing somatostatin receptors (SSTR) 2 and 5 ([Fig. 2](#fig2){ref-type="fig"}). The analysis of encoding ubiquitin-specific protease 8 (USP8) gene revealed no mutations. Postoperatively there was a rapid and complete remission of hypertension, hypokalemia and hyperglycemia. The patient discontinued all the hypoglycemic agents. Plasma ACTH showed a rapid and significant decrease to 5 pg/mL 3 days after surgery. To avoid adrenal insufficiency due to the chronic suppression of the corticotropic axis, transient replacement therapy with hydrocortisone was introduced. There was a rapid recovery of the corticotropic axis that allowed the withdrawal of hydrocortisone after 15 days.Figure 2Histological specimens of the ACTH-secreting pheochromocytoma. (A) Hematoxylin and eosin stain of paraffin-embedded tumor tissue; (B) hematoxylin and eosin stain of hyperplastic adrenal cortex due to ACTH overproduction by the tumor; (C) ACTH immunohistochemistry of the adrenal tumor; (D) pheochromocytoma expression of somatostatin receptor 5 (SSTR5) assessed by specific antibodies; (E) pheochromocytoma cytoplasmatic and membranous expression of somatostatin receptor 2 (SSTR2) assessed by specific antibodies.

Outcome and follow-up
=====================

One month after adrenalectomy, cortisol suppression after dexamethasone 1 mg overnight confirmed the complete resolution of endogenous hypercortisolism. In addition, urinary metanephrines normalized, (105.3 µg/24 h), and CGA decreased to normal values (1.2 nmol/L). At 4-year follow-up, there were not any biochemical, clinical or radiological sign of recurrence.

Discussion
==========

ACTH-secreting pheochromocytoma represents a very rare and distinctive cause of CS, where clinical manifestations due to cortisol and catecholamines excess coexist. About 60 cases have been reported in literature so far ([@bib2]). The syndrome predominantly occurs in women, with typical features including severe hypercortisolism, hypokalemia, rapidly worsening diabetes mellitus and hypertension, large adrenal tumor, and lack of typical phenotype of Cushing syndrome probably due to the fast development of hypercortisolism ([@bib2]). Early diagnosis is often difficult, but is mandatory in order to avoid serious and potentially fatal complications and to guarantee an adequate pre- and post-surgical management. However, consensus regarding the optimal strategy regarding the perioperative clinical workup of such patients is still lacking, due to the rarity of the syndrome and the anecdotal reports presented in literature.

Here we report the efficacy of octreotide administration combined with ketoconazole, doxazosin and atenolol in the management of a 45-year woman with an ACTH-secreting pheochromocytoma, allowing an adequate pre-surgical control of cortisol and catecholamines excess.

Expression of SSTRs has been documented in pheochromocytomas ([@bib3]), but clinical reports on the efficacy of somatostatin analogs published so far have yielded conflicting results ([@bib4], [@bib5]), due, at least in part, to the wide heterogeneity of SSTRs expression in the tumor and to their different affinity to the drugs ([@bib6]). Identification of specific parameters predicting a favorable response to therapy is therefore crucial to select patients who may benefit from somatostatin analogs.

Ruggeri *et al*. ([@bib6]) reported the case of a patient harboring a CRH-secreting pheochromocytoma, successfully treated with octreotide based on a positive octreotide scintigraphy. In that case, immunohistochemistry revealed the expression of SSTR1, SSTR2A, and SSTR2B receptor subtypes on tumor cells. However, Uwaifo *et al*. ([@bib7]) described three cases of ectopic ACTH-dependent CS where pentetreotide scan failed to predict the therapeutic response to somatostatin analogs, with one patient even developing a paradoxical increase in ACTH and cortisol levels after a single octreotide administration. Similar observations have also been reported by other authors ([@bib8]). Uwaifo *et al*. ([@bib7]) suggested performing an octreotide challenge test to predict the ACTH and cortisol response to therapy but, to our knowledge, no reports are available in the literature on this topic in patients with ACTH-secreting pheochromocytoma.

To date, there is no established protocol to acutely test the hormonal sensitivity to somatostatin analogs in CS. We decided to perform a single acute challenge with 100 μg octreotide, similarly to what has been described in acromegaly ([@bib9]). The significant reduction of circulating ACTH levels prompted us to associate octreotide to ketoconazole in the pre-surgical workup of the patient, that in a few days led to a further reduction of ACTH together with cortisol levels. The combination of the two drugs with doxazosin and atenolol allowed an optimal pre- and intra-operative control of blood pressure, pulse rate, glycemic profile and electrolyte homeostasis.

In this setting, the effects of octreotide cannot be isolated from those of the associated drugs. Some authors, however, reported that ketoconazole alone may be unable to adequately control hypercortisolism in ACTH-secreting pheochromocytoma ([@bib10]), exposing the patients to the well-known perioperative complication due to cortisol excess.
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[^1]: ACTH, adrenocorticotropic hormone; CRH, corticotropin-releasing hormone; DST, dexamethasone; IGF-1, insulin like growth factor 1; LH, luteinizing hormone; NSE, neuron-specific enolase; TSH, thyroid-stimulating hormone; UFC, urinary free cortisol.

[^2]: ACTH, adrenocorticotrop-ic hormone.
